A Novel Bioluminescent Assay to Measure ADCC & CDC with the use of Automation

Cell Technology, partners of the Bioassays and Bioanalytical Method Development Event this October, recently published a poster about the novel bioluminescent assay titled: A Novel Bioluminescent Assay to Measure ADCC & CDC with the use of Automation.

Highlights of the poster include:

The success of biologic therapeutics has begun to reshape today’s pharmaceutical market. The first and most successful of these antibody therapies, Rituximab (Rituxan®; Roche/Genentech), showed worldwide sales in 2009 of $5.6 billion (GEN News Highlights, 2011). This, among others including Trastuzumab (Herceptin®; Hoffman-La Roche), have shown great promise for treatment of patients with leukemia, lymphomas, breast, and other cancer types due to their specificity and reduced side effects (Zhou, 2007). One of the mechanisms which play a central role in the response to clinical antibody therapy is Antibody-Dependent Cell-mediated Cytotoxicity (ADCC) (Wang, 2008). This involves the response of natural killer (NK) cells to bind to specific antibody-coated target cells, such as CD20 and HER2 expressing cells, to promote the death of the target cell.

Read the full poster here.

Bioassays and Bioanalytical Method Development Conference this October 1-3, 2012 in Berkley, California.  For more information on this event, download the agenda. To join Cell Technology at the event,register today and mention code XP1768BLOG to save 15% off the standard rate.  If you have any questions about the event, email Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |